A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis Clinical Trial

Official title:

A Phase 1b/2a, Double-blind (Sponsor Open), Randomized, Vehicle-controlled Study of Topically Administered BX005-A in Subjects With Moderate to Severe Atopic Dermatitis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05240300
• Other study ID #: BMX-05-001
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: May 2022
• Est. completion date: June 2023

Study information

• Verified date: February 2022
• Source: BiomX, Inc.
• Contact: Urania Rappo, MD
• Phone: 203-364-2364
• Email: uraniar[@]biomx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of study BMX-05-001 is to evaluate the safety, tolerability, efficacy, and pharmacodynamics of BX005-A compared to vehicle administered topically in adult subjects with moderate to severe atopic dermatitis (AD).

Description:

BMX-05-001 is a double-blind (Sponsor open), randomized, vehicle-controlled, first-in-human, Phase 1b/2a study to evaluate the safety, tolerability, efficacy, and pharmacodynamics of BX005-A compared to vehicle administered topically twice daily for 8 weeks to lesional areas in adult subjects with moderate to severe atopic dermatitis (AD).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 48
• Est. completion date: June 2023
• Est. primary completion date: June 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female = 18 years old

2. Confirmed clinical diagnosis of active AD with at least a 6-month history and clinically stable AD for = 1 month

3. Clinical diagnosis of moderate or severe AD with a vIGA-AD score of = 3 and a lesion vIGA-AD score = 3 in the target AD skin lesion

4. BSA with AD of 2%-30%, excluding scalp

5. Colonized with S. aureus in at least one AD skin lesion

6. Female subjects of non-childbearing potential must meet at least 1 of the following:

postmenopausal status; documented hysterectomy and/or bilateral oophorectomy; or medically confirmed ovarian failure. All other female subjects (including those who have undergone tubal ligation) are of childbearing potential.

7. Female subjects of childbearing potential who have a negative urine pregnancy test

8. Effective contraceptive method for female subjects of childbearing potential and for male subjects

9. Able to understand study procedures and attend all study visits

10. Willing to refrain from use of all other systemic or topical agents for the treatment of AD or the prevention of complications of AD (e.g., secondary infection)

Exclusion Criteria:

1. Active skin infection and/or systemic infection requiring systemic or topical antimicrobial agents and/or a skin drainage procedure, or a history of recurrent bacterial skin infections

2. Other concurrent skin diseases which could interfere with the diagnosis and/or management of AD (e.g., psoriasis, contact dermatitis), or presence of open, chronic non-healing wounds in their treatable AD lesions

3. Known hypersensitivity to study drug, its excipients, simethicone, and/or any emollient to be used in study

4. Planned treatment with a prohibited medication during study, or received a prohibited medication within time frame noted below, prior to first dose of study drug:

Must be discontinued at least 28 Days prior to Day 1:

• Systemic corticosteroids
• Systemic JAK inhibitors and immunosuppressive agents
• Nonbiologic investigational agent or device
• Total body phototherapy

Must be discontinued at least 14 Days prior to Day 1:

• Systemic antimicrobials
• Probiotics and prebiotics
• Prescription skin barrier repair products

Must be discontinued at least 7 Days prior to Day 1:

• Topical therapies for AD
• Topical antimicrobials and antiseptic cleansers
• Use of antibacterial soaps or topical sodium hypochlorite-based products
• Current emollient use (need to convert to study emollient 7 days prior to Day 1)

5. Currently being treated with biologic agents; exception: may be enrolled if dupilumab was discontinued at least 12 weeks prior to Day 1, or if other biologics were discontinued at least 5 half-lives prior to Day 1.

6. Female subjects who are pregnant, breastfeeding, or planning a pregnancy, or are of childbearing potential and not using an effective and allowed form of contraception.

7. Enrolled in another investigational study 30 days prior to Screening or 90 days prior to Screening if investigational agent was a phage product.

8. Other medical and/or psychiatric conditions which makes the subject inappropriate for study participation, increases likelihood that the subject will not be able to comply with study therapy or procedures and/or which places the subject at undue risk

9. Active abuse of alcohol and/or illicit drugs or a history of such abuse that would make it difficult for the subject to comply with study and/or place subject at undue risk

10. Known infection with human immunodeficiency virus (HIV) or other immunodeficiency disorder.

11. Current or prior history of a malignant neoplasm other than previously treated non-melanoma skin cancer

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Biological:
• BX005-A
phage gel

Other:
• Placebo
vehicle gel

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
BiomX, Inc.	Maruho Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability: adverse events (AEs)	The proportion of subjects with any AE, treatment-emergent AE (TEAE), serious adverse event, TEAE leading to study drug discontinuation, TEAE leading to study discontinuation, or death	Through study completion Day 225 (+7 days)
Primary	Safety and tolerability: laboratory abnormalities	The proportion of subjects with abnormalities in laboratory parameters, graded according to the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials	Through study completion Day 225 (+7 days)
Secondary	Change from baseline in log S. aureus density, measured by colony forming units (CFU)/cm2 in the target AD skin lesion in BX005-A vs vehicle groups	S. aureus CFU in target AD skin lesion	Day 1 through Day 71 (± 2 days)
Secondary	Change from baseline in log S. aureus density, measured by quantitative PCR (qPCR)/cm2 in the target AD skin lesion in BX005-A vs vehicle groups	S. aureus qPCR in target AD skin lesion	Day 1 through Day 71 (± 2 days)
Secondary	% change from baseline in the Eczema Area and Severity Index (EASI) score in BX005-A vs vehicle groups	Eczema Area and Severity Index of all lesional skin areas (range 0-72); higher score indicates worse atopic dermatitis	Day 1 through Day 71 (± 2 days)
Secondary	Proportion of subjects who achieve a Validated Investigator Global Assessment AD (vIGA-AD) score of 0 or 1 with at least a 2-grade reduction from baseline in BX005-A vs vehicle groups	vIGA-AD	Day 1 through Day 71 (± 2 days)
Secondary	Change from baseline in SCORing Atopic Dermatitis (SCORAD) index in BX005-A vs vehicle groups	SCORing Atopic Dermatitis index of all lesional skin areas (range 0-103); higher score indicates worse atopic dermatitis	Day 1 through Day 71 (± 2 days)
Secondary	Change from baseline in SCORing Atopic Dermatitis (SCORAD) index of the target AD skin lesion in BX005-A vs vehicle groups	Local SCORing Atopic Dermatitis index (range 0-15); higher score indicates worse atopic dermatitis	Day 1 through Day 71 (± 2 days)